Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Express Scripts
Boehringer Ingelheim
Baxter
Johnson and Johnson

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Rituximab - Biologic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for rituximab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
AstraZenecaPhase 3
JDP Therapeutics, Inc.Phase 2
TerSera TherapeuticsPhase 2

See all rituximab clinical trials

Recent Litigation for rituximab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
CELGENE CORPORATION v. APOTEX INC.2019-06-19
Genentech, Inc. v. Pfizer Inc.2019-04-05

See all rituximab litigation

PTAB Litigation
PetitionerDate
Celltrion, Inc.2018-05-04
Apotex Inc.2018-02-23
Forty Seven, Inc.2018-01-08

See all rituximab litigation

Pharmacology for rituximab

Patent Text Search: US Patents for rituximab

These patents were identified by searching patent claims

Supplementary Protection Certificates for rituximab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 Austria   Start Trial PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE; REGISTRATION NO/DATE: EU/1/13/850 20130805
18C/020 Belgium   Start Trial PRODUCT NAME: EEN GEAFUCOSYLEERD ANTILICHAAM BENRALIZUMAB DAT BINDT AAN DE ALFA-SUBEENHEID VAN DE INTERLEUKIN-5-RECEPTOR; AUTHORISATION NUMBER AND DATE: EU/1/17/1252 20180110
90021-0 Sweden   Start Trial PRODUCT NAME: IBRUTINIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/14/945 20141023
321 Luxembourg   Start Trial PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/14/945 - IMBRUVICA - IBRUTINIB
2015000013 Germany   Start Trial PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE (IMNOVID); REGISTRATION NO/DATE: EU/1/13/850 20130805
2015000061 Germany   Start Trial PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Merck
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.